Biotech Co.* (Symbol) | Pharma Co. (Country) | Type/Product Area | Disclosed Funding (M) | Terms/Details (Date) |
Adprotech Ltd. (UK)* | Elan Corp. plc (Ireland) | Research agreement to evaluate Adprotech's Immudaptin adjuvant technology for use in an immunotherapeutic for Alzheimer's disease | ND | Adprotech will modify selected drug candiates with Immudaptin, and Elan will evaluate their therapeutic potential (1/17**) |
Amersham Pharmacia Biotech* | The Procter & Gamble Co. | Worldwide license agreement to develop a chemistry to expand the percentage of proteins and peptides that can be identified using the Ettan MALDI-ToF mass spectrometry analysis system | ND | The agreement covers a novel chemistry developed by P&G called Peptide Derivatization Technology (12/19) |
Applied Biosystems Group (NYSE:ABI) | Millipore Corp. | Collaboration to develop and market next-generation sample preparation consumables for high-throughput proteomics | ND | Financial details were not disclosed (12/18) |
Aronex Pharmaceuticals Inc. (ARNX) | Sumitomo Pharmaceuticals Co. Ltd. (Japan) | License agreement giving Aronex exclusive rights in the U.S. to a particular class of DACH platinum compounds | $0.5 | Sumitomo will receive a $500,000 up-front payment, milestone payments and royalties based on sales of Aroplatin in the U.S. (12/18) |
Artemis Pharmaceuticals GmbH (Germany)* | DuPont Pharmaceuticals Co. | Nonexclusive license agreement for functional genomics applications of Cre-lox technology | ND | The technology will allow researchers to switch off particular genes in adult animals, then validate the genes' function (1/30**) |
Athersys Inc.* | Bristol-Myers Squibb Co. | Agreement for access to RAGE-VT technology for production of human cell lines expressing six validated drug targets | ND | Athersys gets a licensing fee for each cell line, as well as milestone payments and royalty payments (1/5) |
Aurora Biosciences Corp. (ABSC) | GlaxoSmithKline plc (UK) | Second multiyear ion channel drug discovery technology agreement | ND | Aurora will provide access to its technology for drug discovery and target validation (1/10) |
Biobase GmbH (Germany)* | Aventis Pharma AG (Germany) and N.V. Organon (the Netherlands) | Subscription agreement to the Transfac Professional database | ND | Licenses allow all European affiliates of the companies access to the molecular biological database of gene regulation information (1/11) |
Biophage Inc.* | Nymox Pharmaceutical Corp. | Collaboration on novel antimicrobial treatments and applications development | ND | Further details were not disclosed (1/23) |
BioTrove Inc.* | Pfizer Inc. | Collaboration to develop BioTrove's ultra-high-throughput screening technology for use in Pfizer's research facilities | ND | Pfizer will purchase the developed screening platform (1/12) |
Caliper Technologies Corp. (CALP) | SmithKline Beecham plc (UK) | Collaboration to jointly develop new applications in synthetic chemistry using Caliper's LabChip microfluidic technology | ND | Companies will focus on Caliper's platform to create chip-based chemistry applications for drug discovery (12/19) |
Cambridge Antibody Technology (UK; LSE:CAT) | Elan Corp. plc (Ireland) | Strategic partnership to develop therapeutics to treat neurological diseases and disorders | ND | Under the four-year agreement, the companies will fund all research and development jointly and share commercialization profits equally (1/25) |
Caprion Pharmaceuticals Inc. (Canada)* | MicroMass UK Ltd. (UK; unit of Waters Corp.) | Collaboration to support Caprion's proteomic research by applying Micromass's mass spectrometry technologies | $7.5 | Micromass will make a $7.5M investment in Caprion (11/22) |
Celgene Corp. (CELG) | Novartis Pharma AG (Switzerland) | Research and development agreement for selective estrogen modulator compounds for osteoporosis | ND | Agreement triggers an undisclosed up-front payment to Celgene in the deal that also calls for milestone payments for specific endpoints, as well as royalties; Novartis gains worldwide development and commercial rights for compounds to prevent and treat osteoporosis, and exclusive rights to develop the compounds for additional indications (1/18) |
Celltech Group plc (UK; NYSE:CLL) | Johnson & Johnson | Research and development deal for orally active cancer treatment compounds | ND | The companies will jointly select lead compounds for clinical development from Celltech's library of inhibitors; J&J will support further research and will be responsible for all costs in return for worldwide rights to the compounds (1/22) |
Celltech Group plc (UK; NYSE:CLL) | Pharmacia Corp. | Co-development and marketing deal for the humanized antibody fragment CDP 870 | $280 | Pharmacia will make an up-front payment of $50M; deal includes $230M in potential milestone payments; Pharmacia gains exclusive worldwide rights to CDP 870 and Celltech's other antibody-based anti-TNF-alpha compounds, in all indications (3/5) |
CeNeS Pharmaceuticals plc (UK; LSE:CEN) | Amarin Corp. plc (UK) | Licensing agreement for exclusive North American rights for Moraxen (morphine sulfate) | ND | Terms include an up-front cash payment to CeNeS and a royalty on all future sales; CeNeS will manufacture Moraxen for Amarin at its Scotland facility (1/4) |
CeNeS Pharmaceuticals plc (UK;LSE:CEN) | Shire Pharmaceuticals Group plc (UK) | Research, development and licensing agreement for dopamine D1 agonist program to treat Parkinson's disease | #0.5 (US$0.73) | Agreement includes milestone payments and royalties for CeNeS; Shire also made an equity investment of #150,000 in CeNeS (12/20) |
Cephalon Inc. (CEPH) | The R.W. Johnson Pharmaceutical Research Institute (PRI; unit of Johnson & Johnson) | Access agreement for Cephalon's selective kinases inhibitors technology | ND | Cephalon will receive up-front and milestone payments, in addition to royalties on future product sales; PRI will screen for lead drug candidates and develop and commercialize any products that emerge (1/11) |
Cerep SA (France; Neuer Markt:CEREP) | F. Hoffmann-La Roche Ltd. (Switzerland) | Three-year drug discovery agreement to identify and select drug candidates for development | ND | Cerep will use its technology in the areas of high-throughput screening, pharmacological and pharmaceutical profiling, and classic pharmacology (2/14**) |
Cerus Corp. (CERS) | Pharmaceutical Division of Kirin Brewery Co. Ltd. (Japan) | Collaboration to develop and market products for stem cell transplantation based on Cerus' Helinx technology | $12 | The initial efforts will focus on hematologic malignancies, such as leukemia and lymphoma; Cerus and Kirin will jointly develop the products and Cerus will receive an initial license fee of $1M, plus up to $11M in future payments upon achievement of development milestones; Kirin will fund all development expenses for the Asia-Pacific region and a portion of those for the U.S., and will market the products in the Asia-Pacific region; Cerus will receive a share of product revenues; it retains all marketing rights in the rest of the world (1/24) |
Cetek Corp.* | The R.W. Johnson Pharmaceutical Research Institute (PRI; unit of Johnson & Johnson) | Research collaboration to develop capillary electrophoresis assays for PRI targets and screening against compound libraries from PRI | ND | Financial terms were not disclosed (1/24) |
ChemBridge Corp.* | Kirin Brewery Co. Ltd. (Japan) | Access agreement for PHARMACore | ND | Agreement gives Kirin nonexclusive access to PHARMACore combinatorial lead discovery library; financial terms were not disclosed (11/16) |
Chiron Corp. (CHIR) | Organon Teknika BV (unit of Akzo Nobel NV; the Netherlands) | License agreement for patents of human immunodeficiency virus | ND | Organon gains a worldwide, semi-exclusive license under Chiron's patents of human immunodeficiency virus in assays claiming the detection of nucleic acid sequences for use in clinical diagnostics, excluding use in blood screening (1/18) |
Chiron Corp. (CHIR) | The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson) | Nonexclusive license for the research, development and commercialization of small-molecule therapeutics against a specific hepatitis C virus drug target contained in HCV genomes | ND | The license allows PRI to operate under certain Chiron patents to screen for drug candidates that inhibit the hepatitis C virus (2/2) |
Corixa Corp. (CRXA) | CoPharma Inc. | License, development and commercialization agreement for Corixa's cardioprotectant, RC.552 | ND | CoPharma will develop and commercialize Corixa's RC.552 to treat and prevent cardiac disorders, neuronal damage and ischemia-reperfusion injuries; agreement provides CoPharma with exclusive rights to develop and market RC.552 in the licensed indications in the U.S., Canada, Japan, Australia and New Zealand, as well as countries in Asia, the Middle East and Africa; CoPharma will pay Corixa a license fee, milestone payments and a combination of royalties and profit sharing (1/17) |
Cortex Pharmaceuticals Inc. (OTC BB: CORX) | N.V. Organon (unit of Akzo Nobel NV; the Netherlands) | Exercised option to license the Ampakine technology for use in the field of depression | ND | Agreement includes research and development expenses, milestone components and royalties (1/30) |
CuraGen Corp. (CRGN) | Bayer AG (Germany) | Alliance to discover, develop and jointly commercialize small-molecule drugs to treat obesity and adult-onset diabetes, and a second agreement in which CuraGen will apply its technologies to evaluate early stage drug candidates and preclinical compounds across all disease areas | $124 | CuraGen is to provide 80 drug targets over the first five years, and Bayer will develop small-molecule compounds against the targets; the companies will share expenses and have committed to bring 12 candidates to clinical development; both will jointly fund research and development and commercialization up to $1.34B over 15 years, with the R&D costs being split 56% to 44% between Bayer and CuraGen; the second five-year deal, valued at $124M, includes an $85M equity investment in CuraGen by Bayer AG and $39M in committed funding to CuraGen (1/16) |
Deltagen Inc. (DGEN) | Pfizer Inc. | Collaboration agreement providing access to Deltagen's DeltaBase product | $25 | Pfizer will have nonexclusive access to DeltaBase's information on 750 genes for three years; Deltagen will receive $15M in license access fees, and another $10M if the agreement is extended for another two years (12/22) |
Discovery Partners International Inc. (DPII) | Abbott Laboratories Inc. | Exclusive licensing agreement for Abbott's Micro-Arrayed Compound Screening technology | ND | Abbott will receive royalties on net sales (1/8) |
Diversa Corp. (DVSA) | Dow Chemical Co. | Agreement to develop and produce chiral compounds for active pharmaceutical ingredients, intermediates and other fine chemicals | ND | Diversa will use its technologies to identify and develop enzymes to enhance performance that can be used as biocatalysts to develop pure chiral compounds; Diversa will receive technology access fees, research and development payments, milestone payments and potential royalties (11/7) |
Diversa Corp. (DVSA) | Dow Chemical Co. | Licensing agreement for several enzymes for early stage testing | ND | Diversa received licensing fees and is entitled to royalties (1/8) |
D-Pharm Ltd. (Israel)* | Eli Lilly and Co. | Central nervous system research collaboration to develop novel therapeutics | ND | Companies will use D-Pharm's lipid vector technologies; D-Pharm will reengineer Lilly's lead drug compounds; Lilly will make an undisclosed equity investment in D-Pharm and will have an option to exclusively license resulting compounds; D-Pharm also will receive license fees and development milestones, as well as royalties (3/1) |
EpiGenesis Pharmaceuticals Inc.* | Taisho Pharmaceuticals Co. Ltd. (Japan) | Agreement for Asian development and license | $100 | Deal calls for co-ownership of North American marketing, distribution and commercialization rights, allowing the companies to shop for a partner in North America; the deal includes an equity stake in EpiGenesis, as well as research and milestone payments (2/28) |
Epimmune Inc. | Pharmacia Corp. | Terminated development agreement for a cancer vaccine | ND | Pharmacia agreed to return patent (EPMN) rights and technology to Epimmune (11/14) |
Gene Logic Inc. (GLGC) | Boehringer Ingelheim International GmbH (Germany) | Subscription agreement for multiple segments of the GeneExpress Suite of databases | ND | Boehringer will use the databases in its drug discovery and development programs (12/21) |
Genome Therapeutics Corp. (GENE) | Wyeth-Lederle Vaccines (unit of Wyeth-Ayerst Research, a division of American Home Products Corp.) | Contract agreement to identify the complete DNA map of a pathogenic organism | ND | Genome Therapeutics will generate high-quality DNA sequence information for an entire genome in support of vaccine development projects at Wyeth-Lederle (2/1) |
The FibroGen Group* | Aventis Pasteur SA (France) | Collaboration to develop novel synthetic gelatins using FibroGen technology | ND | Agreement includes up-front payments, program funding, milestone payments, material supply revenues and royalty rights (1/18) |
GeneData AG (Switzerland)* | Novartis Pharma AG (Switzerland) | Multiyear license agreement for the microarray data analysis system, GeneData Expressionist | ND | GeneData installed the system at Novartis research sites (2/15) |
Gene Logic Inc. (GLGC) | LG Chemical Ltd. (Korea) | Subscription agreement to a segment of the GeneExpress database | ND | LG Chemical will use the database in its discovery and development programs and entered a deal with Gene Logic to develop compounds for gastrointestinal disease (12/4) |
Gene Logic Inc. (GLGC) | N.V. Organon (the Netherlands) | Agreement for the Gene-Express database and a research collaboration to develop a custom custom gene expression database | ND | Collaboration is focused on generating and evaluating gene expression information to aid in Organon's development of compounds for reproductive, psychiatric and cardiovascular diseases (12/21) |
Gene Logic Inc. (GLGC) and Affymetrix Inc. (AFFX) | Pfizer Inc. | Research collaboration to co-design and develop a custom microarray | ND | Researchers will design a custom gene expression microarray to be built by Affymetrix and to be made available exclusively to subscribers of the ToxExpress Module (1/11) |
Gene Logic Inc. (GLGC) | Procter & Gamble Pharmaceuticals | Expanded collaboration giving Gene Logic access to human heart tissue samples | ND | Agreement is focused on heart failure and osteoporosis; Gene Logic will include the samples in its GeneExpress Suite and P&G will become a Custom-Suite subscriber (12/22) |
GPC Biotech AG (Germany; FSE:GPC) | Aventis Pharma Drug Innovation and Approval (France) | Research collaboration to identify and validate interaction partners for an Aventis drug discovery target | ND | Aventis will use GPC's PathCode technology to identify and validate interaction partners for an Aventis drug discovery target (12/15) |
GPC Biotech AG (Germany; FSE:GPC) | Byk Gulden (Pharmaceutical unit of Altana AG; Germany) | Five-year target identification and drug discovery alliance to identify tumor-specific targets that cause apoptosis in cancer cells | $100 | The deal includes a single-digit, up-front payment in the millions for GPC, research support over five years and milestone payments, as well as royalties (1/17) |
GPC Biotech AG (Germany; FSE:GPC) | Boehringer Ingelheim International GmbH (Germany) | Alliance to use GPC's technology platform to identify novel targets and their molecular pathways associated with human papillomavirus | $30 | Includes an undisclosed up-front license fee, research funding and development milestones, as well as royalties; deal is potentially worth $30M (1/9) |
Hemosol Inc. (Canada; TSE:HML) | Baxter Biotech S.a.r.l. (unit of Baxter Healthcare Corp.) | Agreement to purchase worldwide patents and intellectual property related to drug delivery technology | ND | Agreement will allow Hemosol to continue development of the technology; Hemosol will make cash payments to Baxter on a progressive basis, along with a 4% royalty on commercial sales of resulting products (10/27) |
HTS Biosystems Inc.* | Mitsubishi Chemical Corp. (Japan) | Strategic relationship in which Mitsubishi will be provided premarket access to the bioanalysis system that uses HTS Biosystem's surface plasmon resonance array technology | ND | Mitsubishi will purchase systems for internal use and hold an option to purchase additional systems (12/5) |
Human Genome Sciences Inc. (HGSI) | Dow Chemical Co. | Agreement to develop a drug for the treatment of B-cell malignancies | ND | Agreement combines Dow's bifunctional chelation agents with HGS's protein discovery, B Lymphocyte Stimulator protein; HGS seeks to develop a radiolabeled complex to treat B-cell malignancies, such as chronic lymphocytic leukemia, multiple myeloma and non-Hodgkin's lymphoma (10/30) |
Hybrigenics SA (France)* | Group de Recherche Servier (France) | Three-year drug target discovery collaboration and license agreement for anticancer drugs | ND | Servier will supply proteins and Hybrigenics will map protein-protein interactions in specific cellular pathways; Servier will provide research funding, up-front cash and milestone payments, as well as royalties (2/8) |
ICN Pharmaceuticals Inc. (NYSE:ICN) | Roche Holding AG (Switzerland) | Agreement to exchange Roche's ownership stake in ICN for an 8.7% ownership stake in ICN's Ribapharm | $120 | Roche has an option to increase its ownership stake in Ribapharm to 17.5% by exchanging additional ICN shares; Roche has about 3.9M shares of ICN (12/21) |
Illumina Inc. (ILMN) | Chevron Research and Technology Co. | Agreement to determine how BeadArray technology can be developed and applied to hydrocarbon processing operations | ND | The study will be funded by Chevron and should complete in early 2002 (2/28) |
ImaRx Therapeutics Inc.* | Elan Corp. plc (Ireland) | Research joint venture to develop and commercialize HydroPlex drug delivery technology for an oncology product | ND | Elan has made an equity investment in ImaRx and provided a credit facility; ImaRx initially will be the majority owner of the joint venture (1/31) |
Immusol Inc.* | Chugai Pharmaceutical Co. Ltd. (Japan) | Functional genomics collaboration for drug discovery relating to cancer metastasis | ND | Immusol's gene inactivation technology will be used to support Chugai's discovery and validation of drug target genes (2/28) |
Incara Pharmaceuticals Corp. (INCR) | Elan Corp. plc (Ireland) | Collaborative agreement to develop OP2000 | ND | The companies will pursue the clinical development of OP2000 while using Elan's Medipad drug delivery system (12/22) |
Incyte Genomics Inc. (INCY) | Corning Inc. | Licensing agreement for rights to Incyte's gene sequence databases and gene patent portfolio | ND | Financial details were not disclosed (1/8) |
InSite Vision Inc. (AMEX:ISV) | Pharmacia Corp. | Agreement to return rights for the ISV-900 technology | ND | InSite regained its rights for the technology for diagnostic and prognostic glaucoma applications; InSite licensed the technology to Pharmacia in November 1999 (12/14) |
InterMune Pharmaceuticals Inc. (ITMN) | Alza Corp. | Purchase agreement for Amphotec | $9 | InterMune is buying Alza's drug Amphotec for $9M, plus undisclosed milestone payments (1/9) |
LifeSpan BioSciences Inc.* | Bristol-Myers Squibb Co. | Subscription agreement for a database on information on the expression and localization of G protein-coupled receptors | ND | BMS will use the database in its efforts toward identification and validation of target genes for its drug delivery programs (2/7) |
LifeSpan BioSciences Inc.* | Merck & Co. Inc. | Access agreement for Life-Span's database of G protein-coupled receptor expression and localization information | ND | Merck will use the data to identify and validate new gene targets for drug discovery (1/23) |
Luminex Corp. (LMNX) | Dynacare Inc. | Strategic partnership to develop and commercialize clinical laboratory assays based on Luminex's LabMAP technology | ND | Terms were not disclosed (2/22) |
Lynx Therapeutics Inc. (LYNX) | Takara Shuzo Co. Ltd. (Japan) | License agreement for Lynx's Megaclone Megasort and Massively Parallel Signature Sequencing Technologies | ND | The license provides Takara with the rights to the technologies exclusively for at least five years, and nonexclusively thereafter; Takara also received a nonexclusive right to manufacture and sell microarrays containing content identified by the Lynx technologies; Takara will make equity purchases in Lynx and will pay technology access fees and royalties; Lynx also will receive payments for the sale of reagents used in applying Lynx's technologies (11/9) |
Maxia Pharmaceuticals Inc.* | The R.W. Johnson Pharmaceutical Research Institute and Ortho-McNeil Pharmaceutical Inc. (units of Johnson & Johnson) | Agreements to discover and develop insulin sensitizers to treat Type II diabetes and related metabolic disorders | ND | Maxia will receive an up-front payment, research and development funding, milestone payments, royalties on product sales and equity investments (1/3) |
Maxygen Inc. (MAXY) | ALK-Abello A/S (the Netherlands) | Research and development deal for recombinant therapeutics for allergy treatment | $80 | Three-year deal calls for license fees, technology access fees, research and development funding and potential milestone payments, as well as royalties (2/8) |
Medarex Inc. (MEDX) and Biosite Diagnostics Inc. (BSTE) | Eli Lilly & Co. | Agreement using Trans-Phage technology to generate high-affinity, fully human antibodies to genomics-derived targets | ND | Lilly will provide targets for 3 years; BioSite will receive technology access fees, fees upon target delivery, annual maintenance fees and milestones and royalties; Medarex will receive license fees and milestones and royalties (1/4) |
Millennium Pharmaceuticals Inc. (MLNM) | F. Hoffmann-La Roche Ltd. (Switzerland) | 3-year agreement focused on development of rheumatoid arthritis diagnostics | ND | Millennium will receive license fees, research funding, milestones and royalties (1/8) |
Myogen Inc.* | Knoll AG (unit of BASF Pharma) | Agreement for the co-development of BSF 208075 | ND | Myogen agreed to pay BASF an up-front fee and will complete Phase II testing in exchange for a share in the potential commercial value; both companies have an option to carry out Phase III trials under certain circumstances (12/18) |
NeuroSearch A/S (Denmark)* | N.V. Organon (the Netherlands) | Alliance to discover, develop and commercialize novel agonists of gamma amino butyric acid (GABA) | US$12.8 | NeuroSearch will receive up to US$12.8M in up-front and milestone payments, as well as potential royalties; Organon is funding all of the research and development costs and will gain exclusive worldwide rights to whatever compounds emerge from the program (11/27) |
NewBiotics Inc.* | Elan Corp. plc (Ireland) | Joint venture agreement to develop a product to treat colorectal cancer in patients who do not respond well to standard chemotherapy | ND | NewBiotics will retain exclusive rights to the product, NB1011, in Japan, Asia and other areas of the world; rights in Europe and North America will be controlled by the joint venture; Elan will invest in NewBiotics and will make certain up-front and milestone payments (2/6) |
Novavax Inc. (AMEX:NOX) | King Pharmaceuticals Inc. | Agreement for exclusive worldwide rights to develop, manufacture and market HPV-16 VLP vaccines | $25 | King gains exclusive worldwide rights and agreed to make a $25M convertible debenture investment in Novavax; it also will pay Novavax a 17% royalty on net sales (12/20) |
Oasis Bioscience Inc.* | Sugen (unit of Pharmacia Corp.) | Research agreement to validate oncology targets for drug discovery | ND | Oasis will develop knockout reagents to investigate and clarify the role of genes (12/1) |
Odyssey Pharmaceuticals Inc.* | Becton, Dickinson and Co. | Licensing agreement for rights to certain substrates for cell-based gene function and high-throughput screening applications | ND | Odyssey has the worldwide right to make, use and sell the compounds, fluorescent and chromogenic sub-strates for beta-lactamase, for cellbased drug discovery and gene function assays (12/20) |
OncoImmunin Inc.* | Wyeth-Ayerst Laboratories (division of American Home Products Corp.) | Research collaboration and license option agreement on image-based caspase high-throughput screening system | ND | Wyeth-Ayerst will make milestone payments and royalties on product sales if it picks up the option to license the drug delivery technology (12/14) |
Orchid BioSciences Inc. (ORCH) | AstraZeneca plc (UK) | Multiyear genotyping agreement to conduct studies using single nucleotide polymorphisms | ND | The agreement includes access to Orchid's SNP databases, development of SNP panels and the use of those panels (2/13) |
Orchid BioSciences Inc. (ORCH) | PerkinElmer Inc. | Exclusive licensing agreement for Orchid's SNP-IT technology for single nucleotide polymorphism scoring applications using fluorescence polarization and energy transfer readout methods | ND | PerkinElmer will produce and sell reagent kits, software and instruments; PerkinElmer also received an option to expand the field of use to include diagnostic assays based on fluorescence methodologies and time resolved energy transfer (1/3) |
Oxford BioMedica plc (UK)* | American Home Products Corp. | Agreement to develop and commercialize a novel anticancer therapy using an Oxford BioMedica antibody | $24 | AHP's division, Wyeth-Ayerst Laboratories, received exclusive development and worldwide marketing rights for all human cancer indications and will assume all costs; the deal, valued at $24M for Oxford, includes up-front payments, license option fees, as well as milestone and royalty payments (1/22) |
Oxford GlycoSciencesplc (UK; OGSI; LSE:OGS) | Pfizer Inc. | Research agreement to discover new biomarkers and drug development targets in Alzheimer's disease and atherosclerosis | ND | OGS will apply its proteomics technology in the collaboration, which is a continuation of the joint research collaboration entered into between the companies in April 1998; Pfizer will provide research funding and will make milestone payments; OGS will grant Pfizer a nonexclusive license to use its databases; Pfizer also will make another equity investment in OGS (12/19) |
Peptech Ltd. (Australia; ASX:PTD) | Knoll AG (Germany; unit of BASF Pharma) and Centocor Inc. (unit of Johnson& Johnson) | Development agreements for two anti-TNF products | A$55 (US$31) | The agreements require Knoll and Centocor to collectively pay up to A$40M to A$55M a year to Peptech, plus another A$38M to A$43M in up-front and milestone payments (1/17**) |
Pharmacopeia Inc. (PCOP) | N.V. Organon (the Netherlands) | Expanded agreement to include a new medicinal chemistry services agreement to optimize hits to lead compounds for Organon | ND | Pharmacopeia will develop synthetic strategies and rapidly synthesize milligram quantities of a significant number of chemical analogs around a lead compound identified by Organon (1/11) |
Pharmagene plc (UK; LSE:PGN) | Bayer AG (Germany) | Drug discovery agreement to generate a dataset to aid the validation of potential drug targets | ND | Bayer will use Pharmagene's knowledge in human tissue to generate the dataset (2/28) |
PharmaSeq Inc.* (Japan) | Mitsui and Co. | Strategic partnership to develop laser light-powered microchips and related instruments | ND | PharmaSeq will receive a multimillion-dollar equity investment from Mitsui (2/12) |
Pharming Group NV (the Netherlands; PHAR) | AM-Pharma (the Netherlands) | Licensing agreement for small antibacterial peptides technology | ND | Pharming will take an equity stake in AM-Pharma (2/20) |
Physiome Sciences Inc.* | Janssen Pharmaceutica NV (unit of Johnson & Johnson) | Agreement to provide cardiac stimulation software to Janssen | ND | The multiyear licensing and development agreement grants J&J rights to test candidate drugs on computers using Physiome's CardioPrism software and physiological information databases (2/5) |
PPD GenuPro (unit of PPD Inc.; PPDI) | Alza Corp. | Exclusive license to dapoxetine for genitourinary therapies, including premature ejaculation | ND | Alza will receive worldwide rights to develop and commercialize dapoxetine and be responsible for manufacturing, clinical, regulatory, sales and marketing costs resulting from the license; GenuPro will receive an undisclosed up-front payment, as well as royalties and milestone payments (12/18) |
Qiagen Genomics Inc. (QGENF) | Daiichi Pure Chemicals Co. Ltd. (Japan) | Purchase agreement for a Masscode system and a nonexclusive license | ND | License is to use related technology in providing SNP genotyping services to clients in Japan (1/10) |
Sequenom Inc. (SQNM) | Hitachi Ltd. (Japan) | Alliance to distribute MassARRAY systems and provide genotyping services in Japan | ND | Hitachi subsidiary Nissei Sangyo Co. Ltd. will become the exclusive distributor of the systems in Japan (12/12) |
Sequenom Inc. (SQNM) | Genomics Institute of the Novartis Research Foundation | Collaboration to validate and map single nucleotide polymorphisms in the mouse genome | ND | Parties will apply the information to identify candidate genes associated with human disease; they will share any intellectual property; GNF bought a MassARRAY system as part of the collaboration (2/26) |
Sequenom Inc. (SQNM) | GlaxoSmithKline plc (UK) | Collaboration to screen DNA samples from Type II diabetes mellitus patients and controls | ND | GlaxoSmithKline will provide about 500 identified single nucleotide polymorphisms and more than 900 DNA samples, and Sequenom will validate the SNPs and screen them against samples using its MassArray technology (1/17) |
Sequitur Inc.* | Bristol-Myers Squibb Co. | Agreement providing access to functional genomics technology | ND | Multiyear, multimillion-dollar agreement in which Sequitur will perform biological screening and supply its anti-sense compounds and methods to Bristol-Myers for use in its target validation studies (1/29) |
Sequitur Inc.* | Pharmacia Corp. | Functional genomics license agreement expanded | ND | Companies expanded the agreement that supplies Sequitur's antisense compounds to Pharmacia for target validation studies; Pharmacia will fund research and will pay antisense material charges and licensing fees (12/4) |
Structural Bioinformatics Inc.* | The R.W. Johnson Pharmaceutical Research Institute (PRI; unit of Johnson & Johnson) | Access agreement for SBI's X-ray crystallography program to advance PRI's internal drug discovery efforts | ND | The agreement covers several undisclosed targets to be solved using X-ray crystallography (1/25) |
SYN X Pharma Inc. (Canada; CDNX:SYY) | Janssen Research Foundation (unit of Johnson & Johnson) | Research collaboration to test SYN X's human stroke markers in Janssen's animal models for stroke and traumatic brain injury | ND | Janssen will make research payments and will purchase products from SYN X for research purposes; if successful, Jannsen will have the option to employ SYN X's proteomics discovery platform to help optimize Janssen's drug development process in central nervous system diseases (1/11) |
Syrrx Inc.* | Genomics Institute of Novartis Research Foundation | Five-year strategic alliance to co-develop automated systems to streamline and industrialize the protein structure determination process | ND | Syrrx gains a worldwide, exclusive license to structural proteomics tools developed by GNF; GNF will take a minority equity position in Syrrx (1/4) |
Trega Biosciences Inc. (TRGA) | F. Hoffmann-La Roche Ltd. (Switzerland) | Licensing agreement for two modules of the iDEA Predictive ADME Simulation System for use in drug discovery | ND | Roche expanded to a three-year global license from its initial license to the absorption module granted earlier this year (1/16)< /TD> |
Tripos Inc. (TRPS) | Bristol-Myers Squibb Co. | Collaboration to design and implement a new, integrated research informatics system | ND | Companies will work to develop a new decision support capability to accelerate drug discovery (12/19) |
Vertex Pharmaceuticals Inc. (VRTX) | Serono SA (Switzerland) | Collaboration to discover, develop and market caspase inhibitors | $95 | Vertex could receive up to $95M to support and expand its drug discovery activities; it also will receive milestone payments; the companies expect to select a first drug development candidate in 2001 (12/12) |
Vivus Inc. (VVUS) | Tanabe Seiyaku Co. Ltd. (Japan) | Licensing agreement for Tanabe's phosphodiesterase type 5 inhibitor compound TA-1790 to treat male and female sexual dysfunction | ND | Vivus has worldwide rights, except in Japan, China and certain Pacific Rim countries, to develop and commercialize TA-1790; Tanabe will be responsible for manufacturing the product and has received an undisclosed up-front payment; it also will receive milestone and royalty payments (3/5) |
Xenogen Corp.* | AstraZeneca plc (UK) | Evaluation license agreement to allow access to Xenogen's technology in oncology | ND | Financial details were not disclosed (1/3) |
Xenogen Corp.* | Pfizer Inc. | Research collaboration to develop methods of identifying potential therapeutic drug targets with the use of transgenic mice | ND | The agreement terminates in December 2003, but can be extended at Pfizer's option for two successive one-year options (1/24) |
XTL Biopharmaceuticals Ltd. (Israel; LSE:XTL) | Pharming Group NV (the Netherlands) | Agreement to jointly evaluate and co-develop human Lactoferrin | ND | Companies will co-develop recombinant human Lactoferrin as a treatment for hepatitis C; financial terms were not disclosed (11/14) |
Zymark Corp.* | Bayer Corp.'s Diagnostic Business Group | Collaboration to provide an automated platform for cell-based compound screening | ND | Collaboration will involve the running of Bayer's QuantiGene assays on Zymark's Staccato Workstation (1/2) |
NOTES |
||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. The chart does include some agreements that occurred before Dec. 14, but were not listed in the previous chart. |
||||
|
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. |
||||
** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed, reported and/or available |
||||
AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||